Pharmaceutical

Arzeda Awarded DARPA Funding to Advance AI-Driven Protein Design for National Security

DARPA Backs Arzeda's AI Platform to Create Novel Proteins with Limited Data SEATTLE, Jan. 23, 2025 /PRNewswire/ -- Arzeda, the…

11 months ago

Petauri Welcomes Mark Levonyak as Executive Vice President, New Business

Rapidly growing pharmaceutical services platform continues to expand team with experienced business development executive. NASHVILLE, Tenn., Jan. 23, 2025 /PRNewswire/…

11 months ago

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON, Jan.…

11 months ago

BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development

FRANKLIN LAKES, N.J. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global…

11 months ago

Veeva and Zifo Partner to Accelerate Quality Control Modernization

Integration will reduce the burden of master lab data configuration, lowering costs and speeding Veeva LIMS implementation PLEASANTON, Calif. and…

11 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with…

11 months ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

11 months ago

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports…

11 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC)…

11 months ago